Atreca CEO and leadership

Tito A. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, he is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, he was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, he was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory. Tito received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.

Tito A. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, he is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, he was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, he was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory. Tito received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.

Tito A. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, he is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, he was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, he was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory. Tito received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.